학술논문

A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B: OR213
Document Type
Academic Journal
Source
Journal of Thrombosis and Haemostasis. Jun 01, 2015 13 Suppl 2:176-177
Subject
Language
English
ISSN
1538-7933